Publication:
Biosimilars

Thumbnail Image

Date

2022-01-01

Journal Title

Journal ISSN

Volume Title

Publisher

Galenos Yayıncılık

Research Projects

Organizational Units

Journal Issue

Abstract

For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.

Description

Keywords

Psoriasis, Biosimilars, Biologics, Science & technology, Life sciences & biomedicine, Dermatology

Citation

Collections


Metrikler

Search on Google Scholar


Total Views

1

Total Downloads

4